These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38900374)
61. CXCL8 enhances the angiogenic activity of umbilical cord blood-derived outgrowth endothelial cells in vitro. Kimura T; Kohno H; Matsuoka Y; Murakami M; Nakatsuka R; Hase M; Yasuda K; Uemura Y; Sasaki Y; Fukuhara S; Sonoda Y Cell Biol Int; 2011 Mar; 35(3):201-8. PubMed ID: 20958269 [TBL] [Abstract][Full Text] [Related]
62. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616 [TBL] [Abstract][Full Text] [Related]
63. Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer. Campbell LM; Maxwell PJ; Waugh DJ Pharmaceuticals (Basel); 2013 Aug; 6(8):929-59. PubMed ID: 24276377 [TBL] [Abstract][Full Text] [Related]
64. The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer. Ji HZ; Liu B; Ren M; Li S; Zheng JF; Liu TY; Yu HH; Sun Y Expert Rev Clin Immunol; 2024 May; 20(5):559-569. PubMed ID: 38224014 [TBL] [Abstract][Full Text] [Related]
65. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105 [TBL] [Abstract][Full Text] [Related]
66. A novel CXCL8 analog is effective in inhibiting the growth via cell cycle arrest and attenuating invasion of Lewis lung carcinoma. Hsu SY; Yu HY; Lee WC; Hsiao CE; Wu CL; Cheng HT; Lin LJ; Li F; Chou YT; Cheng JW Onco Targets Ther; 2019; 12():7611-7621. PubMed ID: 31571912 [TBL] [Abstract][Full Text] [Related]
67. Astragalus mongholicus Bunge and Curcuma aromatica Salisb. inhibits liver metastasis of colon cancer by regulating EMT via the CXCL8/CXCR2 axis and PI3K/AKT/mTOR signaling pathway. Liu F; Liang Y; Sun R; Yang W; Liang Z; Gu J; Zhao F; Tang D Chin Med; 2022 Aug; 17(1):91. PubMed ID: 35922850 [TBL] [Abstract][Full Text] [Related]
68. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition. Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619 [TBL] [Abstract][Full Text] [Related]
69. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325 [TBL] [Abstract][Full Text] [Related]
70. Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Sales KJ; Maldonado-Pérez D; Grant V; Catalano RD; Wilson MR; Brown P; Williams AR; Anderson RA; Thompson EA; Jabbour HN Biochim Biophys Acta; 2009 Dec; 1793(12):1917-28. PubMed ID: 19819266 [TBL] [Abstract][Full Text] [Related]
71. Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? Rotondi M; Coperchini F; Latrofa F; Chiovato L Front Endocrinol (Lausanne); 2018; 9():314. PubMed ID: 29977225 [TBL] [Abstract][Full Text] [Related]
72. Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma. Chen X; Jin R; Chen R; Huang Z Int J Clin Exp Pathol; 2018; 11(2):1036-1045. PubMed ID: 31938199 [TBL] [Abstract][Full Text] [Related]
73. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. Nasser MW; Raghuwanshi SK; Grant DJ; Jala VR; Rajarathnam K; Richardson RM J Immunol; 2009 Sep; 183(5):3425-32. PubMed ID: 19667085 [TBL] [Abstract][Full Text] [Related]
74. Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration. Sloot YJE; Rabold K; Ulas T; De Graaf DM; Heinhuis B; Händler K; Schultze JL; Netea MG; Smit JWA; Joosten LAB; Netea-Maier RT Cell Oncol (Dordr); 2019 Oct; 42(5):691-703. PubMed ID: 31201646 [TBL] [Abstract][Full Text] [Related]
75. The immunological function of CXCR2 in the liver during sepsis. Liu N; Bauer M; Press AT J Inflamm (Lond); 2022 Nov; 19(1):23. PubMed ID: 36451225 [TBL] [Abstract][Full Text] [Related]
76. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer. Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A Front Immunol; 2019; 10():757. PubMed ID: 31031757 [TBL] [Abstract][Full Text] [Related]
77. CXCR2 Is Deregulated in ALS Spinal Cord and Its Activation Triggers Apoptosis in Motor Neuron-Like Cells Overexpressing hSOD1-G93A. La Cognata V; D'Amico AG; Maugeri G; Morello G; Guarnaccia M; Magrì B; Aronica E; D'Agata V; Cavallaro S Cells; 2023 Jul; 12(14):. PubMed ID: 37508478 [TBL] [Abstract][Full Text] [Related]
78. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Zhu YM; Webster SJ; Flower D; Woll PJ Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974 [TBL] [Abstract][Full Text] [Related]
79. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? Rotondi M; Coperchini F; Pignatti P; Sideri R; Groppelli G; Leporati P; La Manna L; Magri F; Mariotti S; Chiovato L J Clin Endocrinol Metab; 2013 Jan; 98(1):308-13. PubMed ID: 23118425 [TBL] [Abstract][Full Text] [Related]
80. PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma. Feng G; Chen C; Luo Y Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]